RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Biocartis Group Revenue 2024

Biocartis Group Revenue

78.28 M EUR

Biocartis Group Dividend yield

Ticker

BCART.BR

ISIN

BE0974281132

WKN

A14R82

In 2024, Biocartis Group's sales reached 78.28 M EUR, a 31.03% difference from the 59.74 M EUR sales recorded in the previous year.

The Biocartis Group Revenue history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)
2025e10326,88
2024e78.2835,36
2023e59.7446,34
202257.4848,16
202148.2729,72
202043.1339,06
201937.4443,04
201827.8144,81
201720.9658,62
201612.156,03
201513.3380,19
20148.4850,65
20138.3377,07
20123.5568,17

Biocartis Group Aktienanalyse

What does Biocartis Group do?

Biocartis Group NV is a Belgian biotechnology company specializing in the development and marketing of innovative diagnostic test systems. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis focuses on various disease areas such as gynecology, oncology, infectious diseases, and immunology. Biocartis' business model is based on a unique diagnostic test system called Idylla, which allows for rapid testing within hours instead of the usual weeks. The Idylla platform also offers high accuracy in identifying biomarkers and easy handling for medical personnel. The company has certified distribution partners worldwide to support the marketing and sales of Biocartis products. Biocartis collaborates closely with pharmaceutical companies, medical laboratories, and clinics globally to deliver the best results for its customers. The company also has partnerships with other biotech companies like Merck and Genomic Health to support the development of its diagnostic tests. Biocartis offers a wide range of diagnostic tests for various cancer types, gynecology, and infectious diseases. Their tests help physicians identify the type and extent of tumors and monitor patients' health status. Through the development and marketing of innovative diagnostic test systems, Biocartis aims to improve disease diagnosis and monitoring, ultimately enhancing treatment for patients worldwide. Overall, Biocartis is a leading company in the biotechnology industry specializing in the development and marketing of innovative diagnostic test systems for various disease areas. With its certified distribution partners and partnerships with other biotech companies, Biocartis has a strong presence in the global market and is well positioned to continue being a key player in the biomedical diagnostics industry. Biocartis Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Biocartis Group's Sales Figures

The sales figures of Biocartis Group originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Biocartis Group’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Biocartis Group's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Biocartis Group’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Biocartis Group Stock

How much revenue did Biocartis Group generate this year?

Biocartis Group has achieved a revenue of 78.28 M EUR this year.

How much was the turnover of the company Biocartis Group compared to the previous year?

The revenue of Biocartis Group has increased by 31.03% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Biocartis Group?

The revenue of Biocartis Group is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Biocartis Group measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Biocartis Group so important for investors?

The revenue of Biocartis Group is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Biocartis Group pay?

Over the past 12 months, Biocartis Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocartis Group is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biocartis Group?

The current dividend yield of Biocartis Group is .

When does Biocartis Group pay dividends?

Biocartis Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biocartis Group?

Biocartis Group paid dividends every year for the past 0 years.

What is the dividend of Biocartis Group?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biocartis Group located?

Biocartis Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biocartis Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biocartis Group from 5/21/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/21/2024.

When did Biocartis Group pay the last dividend?

The last dividend was paid out on 5/21/2024.

What was the dividend of Biocartis Group in the year 2023?

In the year 2023, Biocartis Group distributed 0 EUR as dividends.

In which currency does Biocartis Group pay out the dividend?

The dividends of Biocartis Group are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biocartis Group

Our stock analysis for Biocartis Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocartis Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.